Intégration sociale des immigrants au Canada : conformité des comportements matrimoniaux des jeunes immigrants face à la population canadienne au fil des générations

Près d’un Canadien sur cinq est né à l’étranger. Les niveaux d’immigration ne cessant de croître, la façon dont ces nouveaux venus s’intégreront à leur société d’accueil joue grandement sur l’avenir du pays. Dans les études d'intégration, une attention particulière est portée aux jeunes formant la première et la seconde génération puisqu’ils représentent le lien intergénérationnel entre membres de leurs familles, communautés culturelles et natifs canadiens. Ce mémoire porte sur les tendances liées aux comportements matrimoniaux des différentes générations d’hommes et de femmes provenant de diverses régions géographiques, comparativement à ceux de la population canadienne, incluant l’analyse du rôle que pourraient y jouer les communautés culturelles. En utilisant le recensement de 2001, l'analyse fait une distinction entre le Québec et le reste du Canada, et se concentre sur la probabilité de vivre ou non en union selon l’âge puis, pour ceux en union, la probabilité d’être marié ou en union libre. Les résultats démontrent que les comportements matrimoniaux des immigrants issus d’une union mixte (ayant un parent né au Canada) se conforment plus rapidement à ceux de la population locale que ceux ayant deux parents nés à l’étranger. Aussi, nos résultats révèlent que les immigrants issus de diverses régions géographiques présentent des comportements matrimoniaux et des profils selon le statut générationnel distincts alors que certains d’entre eux ne montrent aucun signe de convergence vers les comportements matrimoniaux des natifs canadiens. Finalement, les résultats liés à la taille et à la présence d’une communauté culturelle varient selon les différents modèles.

Relation entre les jeux de hasard et différentes couches socio-économiques de la population canadienne.

Rapport de recherche présenté à la Faculté des arts et des sciences en vue de l'obtention du grade de Maïtrise en sciences économiques.

Adaptation transculturelle et validation du questionnaire Upper Limb Functional Index (ULFI) pour la population canadienne française

Les troubles musculo-squelettiques du membre supérieur (TMS-MS) peuvent avoir un impact négatif sur l'autonomie d’une personne. À ce jour, il n’existe pas d’outils en français évaluant les limitations d'activités et les restrictions de participation, disposant de bonnes propriétés métrologiques et d'applicabilité dans un contexte clinique marqué par des contraintes de temps. L’Upper Limb Functional Index (ULFI), qui présente de bonnes qualités métrologiques et applicabilité clinique adéquate, s'avère un outil intéressant pour les ergothérapeutes de par son approche centrée sur la personne. Toutefois, il n'était disponible qu'en anglais et en espagnol. La présente recherche, constituée de deux études, visait à adapter l’ULFI à la population canadienne française et à évaluer ses propriétés métrologiques et son applicabilité clinique. La première étude a examiné sa cohérence interne, sa validité convergente et son applicabilité clinique auprès de 50 patients bilingues atteints de TMS-MS. La seconde étude visait à analyser sa fidélité test-retest et sa sensibilité au changement auprès de 60 patients francophones. Les résultats ont révélé que l'ULFI-CF possède des propriétés métrologiques solides : une cohérence interne élevée (α de Cronbach = 0,93), une excellente fidélité test-retest (CCI = 0,87-0,95), une excellente validité convergente (r = 0,70-0,85) et une sensibilité au changement de bonne à excellente (tailles d'effet = 0,49-0,88 et r = 0,64 pour la section 1). L'ULFI-CF démontre également une bonne applicabilité clinique. En conclusion, l’ULFI-CF s’avère un outil pertinent pour les cliniciens œuvrant auprès d’une clientèle canadienne française souffrant d'un TMS-MS dans un contexte clinique marqué par des contraintes de temps.

Prevalence of trachoma in a population of the upper Rio Negro basin and risk factors for active disease

Purpose: To determine the prevalence of trachoma in Sao Gabriel da Cachoeira (SGC), the only urban community of the upper Rio Negro Basin of the Amazon state in Brazil, near the Colombian border, and to investigate the risk factors associated with the active forms of the disease. Methods: A total of 1702 people (440 children up to 9 years and 1069 adults aged 15 years and above) were examined. The sample was selected from a probabilistic household sampling procedure based on census data and a previous study of trachoma prevalence in Sao Gabriel da Cachoeira. A two-stage probabilistic household cluster sample was drawn. Household units were randomly selected within each cluster. A variety of socioeconomic and hygiene variables were studied in order to determine the risk factors for active trachoma in a household. Results: The total prevalence of trachoma was 8.9%. Prevalence of active trachoma (TF and/or TI) in children aged 1-9 years was 11.1% and trachomatous trichiasis in adults aged 15 years and above was 0.19%. Trachomatous scarring reached a peak of 22.4% for subjects between 50 to 60 years of age. Corneal opacity occurred in subjects aged 50 years and older with a prevalence of 2.0%. No sex effect was found on the overall prevalence of trachoma in SGC. Risk factors associated with active trachoma were mainly related to poor socioeconomic indicators. Conclusions: Despite the ubiquitous presence of water, the analysis of the risk factors associated with the active forms of the disease supports the idea that a low personal standard of hygiene and not water availability per se, is the key factor associated with trachoma. Copyright © 2008 Informa Healthcare USA, Inc.

Población económicamente activa = Economically active population

Incluye CD-ROM

América Latina: población económicamente activa: período 1970-2000 = Latin America: economically active population: period 1970-2000

Publicación bilingüe (Español e inglés)

América Latina: población económicamente activa, 1980-2025 = Latin America: economically active population, 1980-2025

Publicación bilingüe (Español e inglés)

América Latina: población económicamente activa, 1980-2025 = Latin America: economically active population, 1980-2025

Publicación bilingüe (Español e inglés)

Gender differences of the spanish adult population in barriers to active living

Proyecto I+D+i DEP19801: Gender differences of the spanish adult population in barriers to active living

Gender differences of the spanish adult population in cultural barriers to active living

Proyecto I+D+i DEP19801: Gender differences of the spanish adult population in cultural barriers to active living

Gender differences of the spanish adult population in barriers to active living

Social research on the needs, barriers and innovations in sport and physical activities to adult women in Spain

Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients

Objective: The objective of the study was to characterise the population pharmacokinetic properties of itraconazole and its active metabolite hydroxyitraconazole in a representative paediatric population of cystic fibrosis and bone marrow transplant (BMT) patients and to identify patient characteristics influencing the pharmacokinetics of itraconazole. The ultimate goals were to determine the relative bioavailability between the two oral formulations (capsules vs oral solution) and to optimise dosing regimens in these patients. Methods: All paediatric patients with cystic fibrosis or patients undergoing BMT at The Royal Children's Hospital, Brisbane, QLD, Australia, who were prescribed oral itraconazole for the treatment of allergic bronchopulmonary aspergillosis (cystic fibrosis patients) or for prophylaxis of any fungal infection (BMT patients) were eligible for the study. Blood samples were taken from the recruited patients as per an empirical sampling design either during hospitalisation or during outpatient clinic visits. ltraconazole and hydroxy-itraconazole plasma concentrations were determined by a validated high-performance liquid chromatography assay with fluorometric detection. A nonlinear mixed-effect modelling approach using the NONMEM software to simultaneously describe the pharmacokinetics of itraconazole and its metabolite. Results: A one-compartment model with first-order absorption described the itraconazole data, and the metabolism of the parent drug to hydroxy-itraconazole was described by a first-order rate constant. The metabolite data also showed one-compartment characteristics with linear elimination. For itraconazole the apparent clearance (CLitraconazole) was 35.5 L/hour, the apparent volume of distribution (V-d(itraconazole)) was 672L, the absorption rate constant for the capsule formulation was 0.0901 h(-1) and for the oral solution formulation was 0.96 h-1. The lag time was estimated to be 19.1 minutes and the relative bioavailability between capsules and oral solution (F-rel) was 0.55. For the metabolite, volume of distribution, V-m/(F (.) f(m)), and clearance, CL/(F (.) fm), were 10.6L and 5.28 L/h, respectively. The influence of total bodyweight was significant, added as a covariate on CLitraconazoie/F and V-d(itraconazole)/F (standardised to a 70kg person) using allometric three-quarter power scaling on CLitraconazole/F, which therefore reflected adult values. The unexplained between-subject variability (coefficient of variation %) was 68.7%, 75.8%, 73.4% and 61.1% for CLitraconazoie/F, Vd(itraconazole)/F, CLm/(F (.) fm) and F-rel, respectively. The correlation between random effects of CLitraconazole and Vd((itraconazole)) was 0.69. Conclusion: The developed population pharmacokinetic model adequately described the pharmacokinetics of itraconazole and its active metabolite, hydroxy-itraconazole, in paediatric patients with either cystic fibrosis or undergoing BMT. More appropriate dosing schedules have been developed for the oral solution and the capsules to secure a minimum therapeutic trough plasma concentration of 0.5 mg/L for these patients.

Paediatric population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in cystic fibrosis and bone marrow transplant patients

Objectives: The aim of the study was to characterise the population pharmacokinetics (popPK) properties of itraconazole (ITRA) and its active metabolite hydroxy-ITRA in a representative paediatric population of cystic fibrosis (CF) and bone marrow transplant (BMT) patients. The goals were to determine the relative bioavailability between the two oral formulations, and to explore improved dosage regimens in these patients. Methods: All paediatric patients with CF taking oral ITRA for the treatment of allergic bronchopulmonary aspergillosis and patients undergoing BMT who were taking ITRA for prophylaxis of any fungal infection were eligible for the study. A minimum of two blood samples were drawn after the capsules and also after switching to oral solution, or vice versa. ITRA and hydroxy-ITRA plasma concentrations were measured by HPLC[1]. A nonlinear mixed-effect modelling approach (NONMEM 5.1.1) was used to describe the PK of ITRA and hydroxy-ITRA simultaneously. Simulations were used to assess dosing strategies in these patients. Results: Forty-nine patients (29CF, 20 BMT) were recruited to the study who provided 227 blood samples for the population analysis. A 1-compartment model with 1st order absorption and elimination best described ITRA kinetics, with 1st order conversion to hydroxy-ITRA. For ITRA, the apparent clearance (ClItra/F) and volume of distribution (Vitra/F) was 35.5L/h and 672L, respectively; the absorption rate constant for the capsule formulation was 0.0901 h-1 and for the oral solution formulation it was 0.959 h-1. The capsule comparative bioavailability (vs. solution) was 0.55. For hydroxy-ITRA, the apparent volume of distribution and clearance were 10.6 L and 5.28 L/h, respectively. Of several screened covariates only allometrically scaled total body weight significantly improved the fit to the data. No difference between the two populations was found. Conclusion: The developed popPK model adequately described the pharmacokinetics of ITRA and hydroxy-ITRA in paediatric patients with CF and patients undergoing BMT. High inter-patient variability confirmed previous data in CF[2], leukaemia and BMT[3] patients. From the population model, simulations showed the standard dose (5 mg/kg/day) needs to be doubled for the solution formulation and even 4 times more given of the capsules to achieve an adequate target therapeutic trough plasma concentration of 0.5 mg/L[4] in these patients.